The Anti-inflammatory Effect of Prophylactic Macrolides on Children With Chronic Lung Disease

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Chronic Lung Disease
Interventions
DRUG

Azithromycin

Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.

DRUG

placebo

Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.

Trial Locations (1)

77030

High Risk Children's Clinic, Houston

All Listed Sponsors
lead

The University of Texas Health Science Center, Houston

OTHER

NCT02544984 - The Anti-inflammatory Effect of Prophylactic Macrolides on Children With Chronic Lung Disease | Biotech Hunter | Biotech Hunter